# A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER

> **NIH NIH N01** · MAYO CLINIC ROCHESTER · 2020 · $15,640

## Abstract

The proposed study shall assess the immunogenicity and the safety of MUC1 vaccine in current and former smokers at high risk for lung cancer. Although safety and immunogenic effects of this vaccine construct were evaluated previously with promising results in individuals at risk for colon cancer the same cannot be assumed however for individuals at risk for lung cancer.

## Key facts

- **NIH application ID:** 10264760
- **Project number:** 261201200042I-P00003-26100013-1
- **Recipient organization:** MAYO CLINIC ROCHESTER
- **Principal Investigator:** PAUL LIMBURG
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $15,640
- **Award type:** —
- **Project period:** 2017-09-01 → 2021-10-01

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10264760

## Citation

> US National Institutes of Health, RePORTER application 10264760, A PILOT STUDY OF MUC1 VACCINE IN CURRENT AND FORMER SMOKERS AT HIGH RISK FOR LUNG CANCER (261201200042I-P00003-26100013-1). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10264760. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*